-
Mashup Score: 8BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM - 2 month(s) ago
– BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe – BridgeBio to receive royalties according to a tiered structure beginning in the low-thirties percent, designed to provide BridgeBio the opportunity to maximally share in the blockbuster potential of acoramidis – BridgeBio will also receive up to $310 Million USD in upfront and near-term milestone payments, and is eligible for additiona
Source: finance.yahoo.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0The Amyloidosis Weekly - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Homepage | US Medical - 2 year(s) ago
Homepage
Source: pfizermedical.pfizerpro.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Like Father, Like Daughter: The Connection Between Genetics and Hereditary ATTR-CM | HFSA - 3 year(s) ago
Sponsored content provided by Pfizer Receiving a diagnosis for a serious and life-threatening disease can be life-altering, especially when you learn the disease is the same one your father had. For Faye, this was the reality she faced after…
Source: hfsa.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Heart Failure Awareness 365: Rare Diseases - 4 year(s) ago
Heart Failure Awareness 365 News In September, HFSA shared information on rare diseases related to heart failure. Explore resources below. View as Webpage Featured Resources Uncovering the Mystery: On
Source: Heart Failure Society of AmericaCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Heart Failure Awareness 365 | HFSA - 4 year(s) ago
The vision of the Heart Failure Society of America is to significantly reduce the burden of heart failure. One way to accomplish this is to spread awareness of the risk factors, methods of prevention, best practices for living with heart failure, and treatment options. In the spirit of the annual HFSA Heart Failure Awareness Week (which takes place in February), HFSA aims to continue awareness…
Source: hfsa.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Uncovering the Mystery: One Man’s Journey With ATTR-CM | HFSA - 4 year(s) ago
Sponsored content provided by Pfizer Can you imagine living 11 years with a life-threatening disease you didn’t know you had? For Walt, that’s how long it took to learn that his symptoms were caused by transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening condition that affects the heart and is associated with heart…
Source: hfsa.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4An Unfamiliar, Rare Disease Associated with Heart Failure in African Americans | HFSA - 4 year(s) ago
Sponsored content provided by Pfizer Heart disease is a leading cause of death for all Americans, but certain minority groups face a greater risk than others. In fact, according to one study, African Americans were 45 percent more likely to die as a result of heart failure-related…
Source: hfsa.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
More interest in #ATTR #CM https://t.co/RhtJpFFVeL